Innocrin Pharmaceuticals, Inc.
www.innocrinpharma.comWe are a privately held, clinical stage pharmaceutical company that develops novel, “best-in-class” oral CYP17 lyase inhibitors for the treatment of castration-resistant prostate cancer (CRPC) and potentially in other hormonally-driven conditions such as breast cancer, endometriosis, or congenital adrenal hyperlplasia.
Read more
We are a privately held, clinical stage pharmaceutical company that develops novel, “best-in-class” oral CYP17 lyase inhibitors for the treatment of castration-resistant prostate cancer (CRPC) and potentially in other hormonally-driven conditions such as breast cancer, endometriosis, or congenital adrenal hyperlplasia.
Read more
Country
State
North Carolina
City (Headquarters)
Durham
Industry
Employees
1-10
Founded
2014
Estimated Revenue
$1 to $1,000,000
Social
Employees statistics
View all employeesPotential Decision Makers
Director , Clinical Operations
Email ****** @****.comPhone (***) ****-****Executive Assistant
Email ****** @****.comPhone (***) ****-****
Technologies
(18)
Reach decision makers at Innocrin Pharmaceuticals, Inc.
Free credits every month!
Innocrin Pharmaceuticals, Inc. FAQ
Durham, United States
Pharmaceutical Manufacturing
